why choose us

First received: August 25, 2023

Clinical Trial: Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

Study Status: Completed

Recruit Status: RECRUITING

Condition: Chronic Obstructive Pulmonary Disease (COPD)

Study Type: INTERVENTIONAL


Official Title: A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants With Symptomatic Chronic

Brief Summary: The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subcutaneously (SC) in adult participants with symptomatic COPD with a history of ? 2 moderate or ? 1 severe exacerbations of COPD in the 12 months prior to enrolment.Participants should be receiving optimised treatment with inhaled maintenance therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) throughout at least the last 3 months prior to enrolment.

Read more